[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (IONS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,399,368
  • Shares Outstanding, K 166,184
  • Annual Sales, $ 943,710 K
  • Annual Income, $ -381,390 K
  • EBIT $ -594 M
  • EBITDA $ -588 M
  • 60-Month Beta 0.41
  • Price/Sales 9.59
  • Price/Cash Flow N/A
  • Price/Book 20.59

Options Overview Details

View History
  • Implied Volatility 45.15% (-7.17%)
  • Historical Volatility 89.59%
  • IV Percentile 42%
  • IV Rank 34.31%
  • IV High 74.24% on 08/20/25
  • IV Low 29.96% on 05/07/26
  • Expected Move (DTE 12) 1.23 (2.18%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 1,287
  • Volume Avg (30-Day) 5,955
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 95,394
  • Open Int (30-Day) 98,048
  • Expected Range 55.33 to 57.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.20
  • Number of Estimates 9
  • High Estimate $-0.98
  • Low Estimate $-1.37
  • Prior Year $-0.80
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
50.01 +13.11%
on 07/22/26
86.74 -34.79%
on 07/08/26
-29.77 (-34.48%)
since 07/07/26
3-Month
50.01 +13.11%
on 07/22/26
86.74 -34.79%
on 07/08/26
-19.46 (-25.60%)
since 05/07/26
52-Week
40.37 +40.10%
on 08/12/25
86.74 -34.79%
on 07/08/26
+15.51 (+37.78%)
since 08/07/25

Most Recent Stories

More News
IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis”...

IONS : 56.56 (+3.80%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

NEW YORK , Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised...

IONS : 56.56 (+3.80%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

NEW YORK , July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS).  Such investors are...

IONS : 56.56 (+3.80%)
Ionis Pharmaceuticals: Q2 Earnings Snapshot

Ionis Pharmaceuticals: Q2 Earnings Snapshot

IONS : 56.56 (+3.80%)
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Frank Bennett, Ph.D., executive vice president and chief scientific officer, will retire effective February 2027. “As...

IONS : 56.56 (+3.80%)
Ionis reports second quarter 2026 financial results and highlights progress on key programs

- TRYNGOLZA ® (olezarsen) demonstrating early sHTG launch momentum, underscoring multi-billion-dollar revenue potential in large patient population – ...

IONS : 56.56 (+3.80%)
Ionis Faces Its Easiest Earnings Comparison in Years With Expectations Already Reset

Barchart Research What to Expect from IONS Earnings IONS Generated July 28, 2026 Current Price $55.30 EPS Estimate $$-1.11 Consensus Rating Moderate Buy Average Move 3.03% Ionis Faces Its Easiest Earnings...

IONS : 56.56 (+3.80%)
Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS

SAN FRANCISCO , July 23, 2026 /PRNewswire/ -- Investors in Ionis Pharmaceuticals, Inc. ( NASDAQ: IONS ) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial...

IONS : 56.56 (+3.80%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

NEW YORK , July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are...

IONS : 56.56 (+3.80%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

NEW YORK , July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are...

IONS : 56.56 (+3.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. Its antisense medicines have been developed/are being developed to treat neurological, cardiovascular and specialty rare diseases.

See More

Key Turning Points

3rd Resistance Point 59.51
2nd Resistance Point 58.05
1st Resistance Point 57.31
Last Price 56.56
1st Support Level 55.11
2nd Support Level 53.65
3rd Support Level 52.91

See More

52-Week High 86.74
Fibonacci 61.8% 69.03
Fibonacci 50% 63.56
Fibonacci 38.2% 58.08
Last Price 56.56
52-Week Low 40.37

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.